Dr. Zoldak presented recent progress in understanding of protein aggregation. Protein aggregation is an adverse effect that affects a wide range of areas. The most serious is the aggregation leading to the development of life-threatening diseases. Such diseases include immunoglobulin G (IgG) light chain amyloidosis or multiple myeloma. In this work, a light chain (hLC) causing renal multiple myeloma was selected to study the effect of reducing agents on the rate of hLC aggregation and the size of aggregates formed.
